Navigation Links
NeuroSigma, Inc. Retains CCG Investor Relations
Date:4/4/2011

LOS ANGELES, April 4, 2011 /PRNewswire/ -- NeuroSigma, Inc. ("NeuroSigma"), a Los Angeles-based medical technology company established to in-license and develop early stage technologies with the potential to transform medical practice, today announced that it has retained CCG Investor Relations to design and execute its strategic communications and investor relations campaign.

"We look forward to working closely with CCG to establish and enhance our profile in the investment community and with all our stakeholders," said Lodwrick M. Cook, Chairman of NeuroSigma.

"Given CCG's track record of professional experience representing a wide spectrum of high-growth, U.S. companies, we are confident that our new partnership will help us achieve those goals," added Dr. Leon Ekchian, President and CEO of NeuroSigma.

Founded by experts in business management and the healthcare industry, NeuroSigma has a growing pipeline of therapies in clinical trials targeting epilepsy, depression, post-traumatic stress disorder (PTSD), and obesity, among others.  NeuroSigma is actively engaged in cutting-edge preclinical research and development, as well as groundbreaking Phase I and Phase II clinical trials at the University of California, Los Angeles (UCLA) and is currently utilizing two distinct therapy platforms:

Trigeminal Nerve Stimulation (TNS) - A proprietary therapy developed at UCLA and exclusively licensed to NeuroSigma.

Deep Brain Stimulation (DBS) – NeuroSigma is supporting the development of new therapies for this platform, which was originally pioneered in France for the treatment of essential tremor and Parkinson's disease.

"We are very pleased to be working with NeuroSigma," said William Coffin, Chairman of CCG Investor Relations.  "At a time when translating important medical research from 'lab bench to bedside' has never been more valuable, NeuroSigma is providing that expertise, working with the very best at institutions like UCLA and bringing their pioneering work to the marketplace for commercialization.  The Company is initially focused on several very important conditions, including epilepsy, which affects 3 million people in the United States and over 50 million worldwide, and major depression, affecting over 18 million American adults and over 120 million worldwide.  With its current team and strong development processes in place, the Company is well positioned for the future."

About NeuroSigma

NeuroSigma is a Los Angeles-based medical technology company established to in-license and develop early stage technologies with the potential to transform medical practice.  Currently we have a specific focus on neuromodulation.  NeuroSigma employs two therapy platforms: Trigeminal Nerve Stimulation (TNS) and Deep Brain Stimulation (DBS).  NeuroSigma has amassed a significant intellectual property portfolio, primarily licensed from the University of California, Los Angeles on a world-wide exclusive basis, including potential therapies for epilepsy, depression and post-traumatic stress disorder (PTSD) via TNS and for PTSD, obesity and cachexia via DBS.  More information about NeuroSigma is online at http://www.neurosigma.com/

About CCG Investor Relations

CCG is a leading global investor relations and strategic communications consulting firm.  In business for more than 30 years, the agency provides a complete range of strategic and investor communications, through our global network to over 100 clients across multiple capital markets.  CCG has been awarded a number of industry honors for its handling of complex investor relations communications matters.  The agency's corporate headquarters is in Los Angeles with additional offices in New York, Beijing, Shanghai, Hong Kong, London, and Tel Aviv.  For further information, contact CCG directly, or visit the Company's web site at http://www.ccgir.com/


'/>"/>
SOURCE NeuroSigma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioDrain Medical, Inc. Retains CFSG1 as Its U.S. Investor Relations Firm
2. Dehaier Medical Retains The Piacente Group as Strategic Investor Relations Consulting Firm
3. SCOLR Pharma, Inc. Retains Nicholas Hall & Company
4. Xenogenics Corporation Retains the Emmes Group to Advise on Fund Raising Efforts
5. Independent Committee of Caraco Board Retains Independent Advisors for Consideration of Sun Pharma Proposal to Purchase Outstanding Shares and Caraco Acknowledges Filing of Purported Class Action Lawsuits
6. Lotus Pharmaceuticals Retains Sichenzia Ross Friedman Ference LLP as General Legal Counsel
7. Anadys Retains Lazard as Strategic Advisor
8. Connectyx Retains Services of CP Capital Securities as It Expands Its Presence in the $5 Billion US Electronic Health Record Market
9. China Pharma Holdings, Inc. Retains CCG Investor Relations
10. Ampio Pharmaceuticals, Inc. Retains Redwood Consultants, LLC to Assist in Shareholder Relations and Strategic Planning
11. Solos Endoscopy, Inc. Retains Expert Resource to Meet Requirements for ISO 13485 Quality Management System Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... April 20, 2017 Eyevensys, a ... first non-viral gene expression technology that enables the safe, ... to address a wide range of ophthalmic diseases, announces ... Healthcare products Regulatory Agency (MHRA) to advance its technology ... ...
(Date:4/19/2017)... , April 19, 2017 Cardiology devices segment is ... period The Cardiology Devices segment is likely to ... 15 Mn in 2018 over 2017. By the end of ... valuation close to US$ 700 Mn, expanding at a CAGR ... dominated the Asia Pacific reprocessed medical ...
(Date:4/19/2017)... 19, 2017 Global Prostate Cancer Therapeutics ... the prostate cancer therapeutics market analyzes the current ... prevalence of prostate cancer, launch of promising emerging ... of new drugs & therapeutic biological products, and ... to lesser side effects are some of the ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... 28, 2017 , ... Ushio America proudly introduces the new ... energy-saving solution for F32T8 fluorescent lamps on most instant-start and programmed-start electronic ballasts ... rated lamps utilize the existing electronic ballast, saving labor and maintenance costs. It’s ...
(Date:4/28/2017)... ... April 28, 2017 , ... From April 30 to ... Care Medicine will host industry leaders for the annual spring Convention & Expo, ... the industry adapt to the issues currently affecting urgent care and on-demand healthcare. ...
(Date:4/28/2017)... ... 28, 2017 , ... Researchers at Moffitt Cancer Center ... CentrePoint Data Hub in a sample of participants enrolled in an ongoing cancer ... monitoring solutions for the global scientific community. The company’s new CentrePoint Data Hub ...
(Date:4/28/2017)... ... , ... Rob Lowe is a popular actor that has been in many ... educational purpose as the host of the “Informed” series. The program focuses on many ... the series focuses on thyroid cancer. , Although thyroid cancer is an uncommon type ...
(Date:4/27/2017)... Jacksonville, Florida (PRWEB) , ... April 27, 2017 , ... ... qualified candidates. But they will rapidly reject an outdated healthcare executive resume. , “If ... good look at your executive resume and wondering if it’s as ready as you ...
Breaking Medicine News(10 mins):